Physician profile
Mohammad A Abidi
NPI 1295153690
$2,023.76
in general payments reported to CMS, 2019-2025
21 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $78.50 · 2021: $98.50 · 2022: $247 · 2023: $411 · 2024: $392 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.06 | 2019-2024 | Skyrizi |
| Boston Scientific Corporation | $196.45 | 2019-2025 | Spyglass |
| Madrigal Pharmaceuticals | $148.24 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $138.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.01 | 2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $105.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $101.73 | 2023 | Xarelto |
| La Jolla Pharmaceutical Company | $100.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $98.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $54.44 | 2023 | |
| Ardelyx, INC. | $51.37 | 2023 | Ibsrela |
| Janssen Biotech, INC. | $43.09 | 2022-2024 | Tremfya |
| Daiichi Sankyo INC. | $40.08 | 2019-2020 | |
| Exact Sciences Corporation | $22.46 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $18.09 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $16.16 | 2020 | |
| Alfasigma USA, INC. | $15.92 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.16 | 2024 | Voquezna |
| Novo Nordisk INC | $14.76 | 2024 | Wegovy |
| Janssen Scientific Affairs, LLC | $14.46 | 2022 | |
| Shire North American Group INC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Abidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.